Download MendeleySubstituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia.
Pfefferkorn, J.A., Choi, C., Larsen, S.D., Auerbach, B., Hutchings, R., Park, W., Askew, V., Dillon, L., Hanselman, J.C., Lin, Z., Lu, G.H., Robertson, A., Sekerke, C., Harris, M.S., Pavlovsky, A., Bainbridge, G., Caspers, N., Kowala, M., Tait, B.D.(2008) J Med Chem 51: 31-45
- PubMed: 18072721
- DOI: https://doi.org/10.1021/jm070849r
- Primary Citation of Related Structures:
2R4F - PubMed Abstract:
In light of accumulating evidence that aggressive LDL-lowering therapy may offer increased protection against coronary heart disease, we undertook the design and synthesis of a novel series of HMG-CoA reductase inhibitors based upon a substituted pyrazole template. Optimizing this series using both structure-based design and molecular property considerations afforded a class of highly efficacious and hepatoselective inhibitors resulting in the identification of (3 R,5 R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2 H-pyrazol-3-yl]-3,5-dihydroxy-heptanoic (PF-3052334) as a candidate for the treatment of hypercholesterolemia.
Organizational Affiliation:
Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA. jeffrey.a.pfefferkorn@pfizer.com
